Subgroup analysis from the EMPA-REG OUTCOME study demonstrated consistent risk reductions for CV outcomes, mortality, and renal outcomes with empagliflozin in Asian patients with T2DM and established CV disease [36,37,38,39,40]
The answer is encouraging, but we must be careful
Determining the effects of combined liraglutide and phentermine on metabolic parameters, blood pressure, and heart rate in lean and obese male mice
Because the review of 48 studies, although comprehensive, looked at a wide and diverse group of people -- from those with conditions such as diabetes and kidney disease, and those with different starting and end points and who took different medications -- the conclusions drawn also highlight its limitations
Neuronal and intracellular signaling pathways mediating GLP-1 energy balance and glycemic effects